Clinical experience with TNF blockers;Klinische Erfahrung mit TNF-Blockem

Zeitschrift fur Rheumatologie

Volumn 60, Issue 5, 2001, Pages 319-325

  Forster, A ^a   Michel, B A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Efficacy; Rheumatoid arthritis; Safety; TNF blockers

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA2; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; HUMAN; IMMUNOLOGY; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; ENGLISH ABSTRACT; HUMAN; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR;

EID: 0035488602     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003930170031     Document Type: Article

References (31)

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Chester Wasko M, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593
2. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352
3. Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal and TNF-a antibody with interleukin-1 receptor antagonist Eur Cytokine Netw 6:225-230
4. Charles PJ, Smeenk RJT, De Jong J, Feldman M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a. Arthritis Rheum 43:2383-2390
5. Choy EHS, Panayi GS (2001) Cytokine pathway and joint inflammation in rheumaoid arthritis. N Engl J Med 344:907-916
6. Cush JJ, Spiera R (2000) Etanercept update on recent "dear doctor" safety letter. American College of Rheumatology hotline
7. Den Broeder AA, Joosten LAB, Saxne T, Fenner H, Van Riel PLCM, Van de Putte LBA, Barrera P (2000) Effect of long-term anti-TNF monotherapy on radiologic course and on markers of cartilage breakdown and endothelial activation in RA. Arthritis Rheum 43:Suppl:S227
8. Feldmann M, Maini RN (2001) Anti-TNFa therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163-196
9. Franklin CM (1999) Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. Semin Arthritis Rheum 29:172-182
10. Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, Van de Putte LBA, Visher TL, Weisman MH (2000) Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis. Ann Rheum Dis 59(suppl 1):1-2
11. Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57:945-966
12. Kavanaugh A, St. Clair EW, Me Cune WJ, Braakman T, Lipsky P (2000) Chimeric anti-tumor necrosis factor-a monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 27:841-850
13. Kempeni J (2000) Update on D2E7: a fully human anti-tumour necrosis factor monoclonal antibody. Ann Rheum Dis 59(suppl 1):i44-i45
14. Lipsky P, Van der Heijde D, St. Clair W, Smolen J, Furst D, Kalden J, Weisman M, Breedveld F, Emery P, Keystone E, Harriman G, Maini R (2000) 102-Wk clinical & radiologic results from the ATTRACT trial: a 2 year randomized, controlled, phase 3 trial of infliximab in pts with active RA despite MTX. Arthritis Rheum 43 (suppl):S269
15. Lipsky PE, Van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldman M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594-1602
16. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342:763-769
17. Maini RN, Breedveld FC, Kalden JR, Smolen IS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldman M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
18. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldman M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939
19. Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341-1359
20. Mease PJ, Goffe BS, Metz J, Vander-Stoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390
21. Moreland LM, Cohen SB, Baumgartner SW, Schiff MH, Tindall EA, Bulpitt K, Burge DJ (2000) Long-term use of Enbrel® in patients with DMARD-refractory rheumatoid arthritis. Arthritis Rheum 43(suppl): S227
22. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141-147
23. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischman RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange MLM, McDonell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 130:478-486
24. Ogilvie AIJ, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Lüftl M (2001) Treatment of psoriatic arthritis with antitumour necrosis factor-a antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144:587-589
25. Richter C, Wanke L, Steinmetz J, Reinhold-Keller E, Gross WL (2000) Mononeuritis secondary to rheumatoid arthritis responds to etanercept. Rheumatology 39:1436-1437
26. Schiff M, Mease P, Weinblatt M, Moreland L, Burge D (2000) Randomized controlled trial of 25 mg vs 50 mg Etanercept twice weekly in rheumatoid arthritis. Arthritis Rheum 43(suppl): S227
27. Shergy W, Isern R, Cooley D, Harshbarger J, Huffstutter J, Smith D, Warner D, Quinn A, Keenan G, Schaible T (2000) Infliximab ameliorates clinical signs and symptoms of rheumatoid arthritis within 48 hours: results of the PROMPT study. Arthritis Rheum 43(suppl):S227
28. The lenercept multiple sclerosis study group and the university of british Columbia MS/MRI analysis group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465
29. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor a (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428-433
30. Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H (2000) Crohn's disease associated with spondyloarthropathy: effect of TNF-a blockade with infliximab on articular symptoms. Lancet 356:1821-1822
31. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KI, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253-259